Pharsight

Januvia generic

Januvia is an anti-diabetic drug owned by Merck Sharp Dohme. The drug contains the active ingredient sitagliptin phosphate. It received its first market authorization on 16 October, 2006. Among the 6 drug patents Januvia holds, 2 are still active while 4 have expired.

When will Januvia generic be available?

The Januvia generic version will only be possible after the expiration of its last active patent. Currently, the patent that's affecting the generic release date the most is US7326708*PED, titled as 'Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor', which is expected to expire on 24 May, 2027.

Januvia uses

Januvia is used in the treatment of type 2 diabetes mellitus. The active ingredient, sitagliptin phosphate, works as a dipeptidyl peptidase-IV inhibitor. It can also be combined with a ppar-gamma agonist, metformin, a sulfonylurea, or insulin for greater effectiveness in treating type 2 diabetes mellitus.

Januvia patent expiration

Januvia's significant patents include US7326708*PED and US6699871. These primarily and pedantically deal with the drug's chemistry in acting as a dipeptidyl peptidase-IV inhibitor for the treatment or prevention of diabetes. Most crucial for the Januvia generic release is the US7326708*PED that expires on 24 May, 2027. A detailed summary of Januvia's patents is given below:

EPO Oppostions filed on Januvia

Litigations filed on Januvia

Januvia dosage

Want to ask something?